Accessibility Menu
Medexus Pharmaceuticals logo

Medexus Pharmaceuticals(TSX) MDP

Market CapCA$160.20MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2013)-33%
5 Year+6%
1 Year+85%
1 Month+1%
CA$5.06
+1.61%
+0.08Today
Medexus Pharmaceuticals last closing stock price
MetricPriceDate
Last closeCAD 5.062026-08-07
Medexus Pharmaceuticals stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0.8%CAD 5.022026-07-31
1 month+1.2%CAD 5.002026-07-08
3 month+25.56%CAD 4.032026-05-08
Year to date+73.88%CAD 2.912025-12-31
1 year+85.35%CAD 2.732025-08-07
3 year+56.17%CAD 3.242023-08-08
5 year+6.08%CAD 4.772021-08-06
Since inception-32.53%CAD 7.502013-12-27

Medexus Pharmaceuticals Financials at a Glance

Market Cap

CA$160.20MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$99.33M

Net Income (TTM)

-$2.39M

EPS (TTM)

-CA$0.10

P/E Ratio

-49.41

Dividend

CA$0.00

Beta (Volatility)

0.93 (Low)

Price

CA$5.06

Volume

61,302

Open

CA$4.84

Previous Close

CA$5.06

Daily Range

CA$4.84 - CA$5.09

52-Week Range

CA$2.47 - CA$5.25

Estimated Earnings Date

Aug 10, 2026

MDP News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Medexus Pharmaceuticals

Medexus Pharmaceuticals Inc. operates as a pharmaceutical company in Canada and the United States, focusing on various therapeutic areas including allergy, dermatology, hematology, oncology, rheumatology, and rare diseases. The company offers a diverse portfolio of products aimed at addressing significant medical needs.

Products and Services
  • IXINITY, a therapeutic for hemophilia B
  • Rasuvo and Metoject, treatments for rheumatoid arthritis
  • Gleolan, an optical imaging agent for glioma surgery
Growth Outlook
  • Recent quarterly revenue reached $24.7 million, indicating stable demand
  • Strong product pipeline supports potential market expansion
  • Focus on rare diseases may enhance competitive positioning
Financial Highlights
  • Trailing twelve months revenue of $99.5 million reflects consistent performance
  • Operating income margin improved to 6.7% in the latest quarter
  • Cash flow from operations was $3.8 million, demonstrating operational efficiency
Medexus Pharmaceuticals Inc. has established itself as a key player in the pharmaceutical industry, with a focus on innovative treatments across multiple therapeutic areas. The company's diverse product offerings, including treatments for hemophilia and rheumatoid arthritis, position it well within the healthcare market. Recent financial performance indicates a solid revenue stream and improving operational metrics, which may attract potential investors looking for growth opportunities in the pharmaceutical sector. The strategic focus on rare diseases and a robust product pipeline further enhance the company's prospects for future growth.
AI Generated • Jul 24, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

90

CEO

Kenneth d’Entremont

Website

www.medexus.com

Headquarters

Toronto, ON M5C 1C3, CA

MDP Financials

Key Financial Metrics (TTM)

Gross Margin

54.78%

Operating Margin

5.62%

Net Income Margin

-2.41%

Return on Equity

-4.64%

Return on Capital

8.19%

Return on Assets

-1.63%

Earnings Yield

-2.02%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

CA$160.20MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

31.66M

Volume

61.30K

Avg. Volume

44.76K

Financials (TTM)

Gross Profit

$54.41M

Operating Income

$5.58M

EBITDA

$12.59M

Operating Cash Flow

$18.87M

Capital Expenditure

-$15.15M

Free Cash Flow

$3.72M

Cash & ST Invst.

$6.52M

Total Debt

$22.26M

Medexus Pharmaceuticals Performance Analysis

Medexus Pharmaceuticals annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20232023-03-31USD 142,998,44548.7%
20242024-03-31USD 152,490,6276.6%
20252025-03-31USD 150,683,099-1.2%
20262026-03-31USD 137,286,374-8.9%
Medexus Pharmaceuticals sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q12025-06-30-0.6%
Q22025-09-300.5%
Q32025-12-312.4%
Q42026-03-31-2.7%
Medexus Pharmaceuticals annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20232023-03-31USD 0.08N/A
20242024-03-31USD -0.01N/A
20252025-03-31USD 0.12N/A
20262026-03-31USD -0.10N/A
Medexus Pharmaceuticals sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q12025-06-30176.6%
Q22025-09-30-162.5%
Q32025-12-31125.0%
Q42026-03-31-3540.0%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2026YOY CHG

Revenue

$24.65M

-0.4%

Gross Profit

$13.27M

+6.8%

Gross Margin

53.84%

N/A

Market Cap

CA$160.20MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

CA$1.78M

N/A

Employees

90

N/A

Net Income

-$2.68M

-383.7%

EBITDA

$475.00K

-87.1%

Quarterly Fundamentals

Name
Q4 2026YOY CHG

Total Cash

$6.52M

-72.8%

Total Debt

$22.26M

-40.1%

Accounts Receivable

$14.86M

+11.7%

Inventory

$33.30M

-5.6%

Long Term Debt

$20.05M

+10026.8%

Short Term Debt

$2.21M

-94.0%

Return on Assets

-1.63%

N/A

Return on Invested Capital

5.96%

N/A

Free Cash Flow

-$11.22M

-604.5%

Operating Cash Flow

$3.79M

+66.4%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
CRDL.TOCardiol Therapeutics Inc.
CA$1.99+3.11%
DB.VDecibel Cannabis Company Inc.
CA$0.11+4.76%

Trending Stocks

Symbol / CompanyPricePrice Chg
SPCXSpace Exploration Technologies
$133.11+0.16%
TTDThe Trade Desk
$13.80-0.22%
NVDANvidia
$223.96+0.02%
TLTiShares Trust - iShares 20+ Year Treasury Bond ETF
$82.76+0.00%

Questions About MDP

What is the current price of Medexus Pharmaceuticals?

Medexus Pharmaceuticals is trading at CA$5.06 per share.

What is the 52-week range for Medexus Pharmaceuticals?

Over the past 52 weeks, Medexus Pharmaceuticals has traded between CA$2.47 and CA$5.25.

How much debt does Medexus Pharmaceuticals have?

As of the most recent reporting period, Medexus Pharmaceuticals reported total debt of $31.07M.

How much cash does Medexus Pharmaceuticals have on hand?

Medexus Pharmaceuticals reported $9.10M in cash and cash equivalents in its most recent financial results.

What is Medexus Pharmaceuticals’s dividend yield?

Medexus Pharmaceuticals does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services